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Available online - 6 August 2019ABSTRACT
Introduction: Improved outcome has been shown in pa-
tients with synchronous oligometastatic (sOM) NSCLC when
treated with radical intent. As a uniform definition of sOM
NSCLC is lacking, we developed a definition and diagnostic
criteria by a consensus process.Methods: A pan-European multidisciplinary consensus
group was established. Consensus questions were built on
the basis of current controversies, and definitions were
extracted from a survey, cases and a systematic review.
This statement was formulated during a consensus
meeting.
December 2019 Definition of sOM NSCLC—Consensus Report 2111Results: It was determined that definition of sOM NSCLC is
relevant when a radical treatment that may modify the
disease course (leading to long-term disease control) is
technically feasible for all tumor sites with acceptable
toxicity. On the basis of the review, a maximum of five
metastases and three organs was proposed. Mediastinal
lymph node involvement was not counted as a metastatic
site. Fludeoxyglucose F 18 positron emission tomography–
computed tomography and brain imaging were considered
mandatory. A dedicated liver magnetic resonance imaging
scan was advised for a solitary liver metastasis, and thor-
acoscopy and biopsies of distant ipsilateral pleural sites
were recommended for a solitary pleural metastasis. For
mediastinal staging, fludeoxyglucose F 18 positron emission
tomography–computed tomography was deemed the mini-
mum requirement, with pathological confirmation recom-
mended if this influences the treatment strategy. Biopsy of a
solitary metastatic location was mandated unless the
multidisciplinary team is of the opinion that the risks
outweigh the benefits.
Conclusion: A multidisciplinary consensus statement on
the definition and staging of sOM NSCLC has been formu-
lated. This statement will help to standardize inclusion
criteria in future clinical trials.
 2019 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
Keywords: Non–small cell lung cancer; Oligometastatic dis-
ease; Consensus definition; StagingIntroduction
There is a common belief that patients with meta-
static NSCLC cannot be treated successfully with curative
intent. However, for years patients presenting with a
solitary brain or adrenal metastasis were pragmatically
treated with local radical treatment (LRT), as retro-
spective series (and many anecdotes) demonstrated
long-term overall survival (OS) in some of these pa-
tients.1–4 Favorable outcomes of LRT in patients with
NSCLC presenting with up to five metastatic sites were
shown in several series, mainly retrospective, with a 5-
year OS rate around 30%.2,5
The concept of a clinically significant state of oligo-
metastasis was first described in 19956: it was proposed
that these patients have an intermediate state of meta-
static potential and could potentially benefit from LRT.
This concept was thought to be rare in metastatic dis-
ease; however, because of the implementation of more
sensitive imaging methods (such as fludeoxyglucose F
18–positron emission tomography [18F-FDG PET]) in
daily practice, patients with synchronous oligometastatic
disease (sOM) are being identified more frequently.7 Inthe past few years the concept of treatment of sOM
NSCLC with LRT has evolved. The continuing interest has
been fueled by the increasing number of treatment
strategies, with widespread introduction of minimally
invasive surgery and stereotactic radiotherapy. sOM
NSCLC was addressed as a special treatment entity in the
2016 and 2018 European Society of Medical Oncology
guidelines8,9 and in the National Comprehensive Cancer
Network guideline.10 In the last TNM classification
(eighth edition), a new M subclassification was intro-
duced; according to this subclassification, the category
M1b11 is used for patients with a solitary extrathoracic
metastasis showing an improved survival compared with
that of patients with multiple extrathoracic metastases
(M1c), whereas the category M1a is used for patients
with contralateral pulmonary nodule(s) without extra-
thoracic metastases.
After several prospective single-arm clinical
studies,12–14 two recent randomized phase II trials (with
49 and 29 randomized patients, respectively) showed
improved progression-free survival (PFS) in patients
with sOM NSCLC when treated with LRT versus with
systemic treatment only.15,16 In both trials non-
progressing patients were randomized between LRT or
observation after completing first-line chemotherapy. In
the trial reported by Gomez et al., 48 patients were
randomized and showed a significant difference in PFS of
4 versus 12 months. Recently, the OS data were pre-
sented; the data showed a median OS of 41.2 months for
the LRT arm and 17 months for the control arm.17 The
second study was stopped early (after enrollment of 29
patients), as it met an early stringent stopping rule of
improved local control (PFS 9.7 months for stereotactic
ablative radiotherapy þ maintenance chemotherapy
versus 3.5 months in the maintenance chemotherapy–
alone arm [p ¼ 0.01]).16
Since these studies, sOM NSCLC has become estab-
lished as a regular topic of debate at lung cancer con-
ferences. However, different definitions and staging
procedures have been used in the published clinical
trials. A search on ClinicalTrials.gov (in December 2018)
revealed that the ongoing clinical trials are all using
varying and different definitions of sOM NSCLC and the
staging procedures to categorize oligometastatic disease
vary, as is also true for the recent published phase II
studies (Table 1).12,13,15,16
As long-term survival may nowadays be achieved
with innovative strategies, including targeted treatment
and immunotherapy-based combinations, sOM NSCLC
may represent an opportunity to develop curative-intent
multimodal treatment. Uniformity in defining sOM
NSCLC and an agreement on mandated staging of these
patients is required to unify taxonomy. Importantly, such
Table 1. Definition and Staging Procedures Recommended in Recently Published and Ongoing Clinical Trials on Synchronous Oligometastatic NSCLC
Trial Authors Country Trial No. Phase
Definition of
No. of Metastasis
Mandated
18F-FDG
PET
Mandated
Brain
Imaging
Concurrent and Nonconcurrent
Chemoradiotherapy or Radiotherapy Alone for
Patients with Oligometastatic Stage IV Non–
Small Cell Lung Cancer (NSCLC)
De Ruysscher et al.
(2012)12
The Netherlands NCT
01282450
2 <5 Yes Yes
Surgery and/or Radiation Therapy or Standard
Therapy and/or Clinical Observation in Treating
Patients with Previously Treated Stage IV Non–
Small Cell Lung Cancer
Gomez et al. (2016)15 United States NCT01725165 2 3a (LNs count as 1
metastatic site)
Nob Nob
Phase II Study of Pembrolizumab after Curative
Intent Treatment for Oligometastatic Non–Small
Cell Lung Cancer
Bauml et al. (2018)13 United States NCT02316002 2 NR NR NR
Maintenance Chemotherapy Versus Consolidative
Stereotactic Body Radiation Therapy (SBRT)
plus Maintenance Chemotherapy for Stage IV
Non–Small Cell Lung Cancer (NSCLC): A
Randomized Phase II Trial
Iyengar et al. (2018)16 United States NCT02045446 2 6c Nob NR
Stereotactic Ablative Radiotherapy for
Oligometastatic NSCLC (SARON)
— United Kingdom NCT02417662 3 3 Yes Yes
Local Nonsalvage Radiotherapy for Synchronous
Oligometastatic Non–Small Cell Lung Cancer
— People's Republic of
China
NCT03119519 2 5 NR NR
Phase Ib Study of Stereotactic Body Radiotherapy
(SBRT) in Oligometastatic Non-Small Lung
Cancer (NSCLC) With Dual Immune Checkpoint
Inhibition
— United States NCT03275597 1b 6 Extracranial sitesd NR NR
Radical Treatment of Synchronous Oligometastatic
Non–Small Cell Lung Carcinoma
— Mexico NCT02805530 Single-
arm
5 NR NR
Stereotactic Body Radiation Therapy (SBRT) in
Newly Diagnosed Advanced-Staged Lung
Adenocarcinoma (Sindas)
— People's Republic of
China
NCT02893332 3 5 (inclusive primary site; lymph
nodes are considered as a
metastatic site)
NR NR
Note: Search of ClinicalTrials.gov was performed on December 14, 2018, using search terms oligometastatic AND lung cancer|recruiting studies.
aAfter first-line systemic therapy.
bPositron emission tomography–computed tomography and/or brain magnetic resonance imaging were suggested but not mandated.
cSix active extracranial sites after no more than three sites in the liver or lung.
dA site may have multiple tumor lesions within it as long as the gross tumor volume of the site is 8 cm or less and can be covered in an acceptable stereotactic body radiation therapy field.
18F-FDG PET, fludeoxyglucose F 18 positron emission tomography; NR, not reported on ClinicalTrials.gov; LN: lymph node.
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December 2019 Definition of sOM NSCLC—Consensus Report 2113agreement will help to standardize inclusion criteria in
future clinical trials. Therefore, we aimed to develop a
definition of sOM NSCLC by following a consensus pro-
cess. In addition, a statement was made on the required
optimal staging procedures.Methods
The process to develop a consensus definition of sOM
NSCLC was initiated by the European Organization of
Research and Treatment of Cancer (EORTC) Lung Cancer
Group (LCG) in October 2017. A multidisciplinary group
of 35 European thoracic oncology experts (pulmonolo-
gists, medical oncologists, radiation oncologists, thoracic
surgeons, and radiologists) from different societies
(EORTC LCG, EORTC Radiotherapy Group, International
Association for the Study of Lung Cancer, European
Respiratory Society, European Society for Radiotherapy
and Oncology, and European Society of Medical
Oncology) and different European countries were invited
to participate.
A meeting to define the statement was planned, and
as a preparation for this meeting, a multistep process
involving a systematic review was followed and a survey
and real-life sOM SCLC cases were distributed (described
in detail later). Results of this preparatory work were
used to identify areas of consensus and areas for further
discussion (Fig. 1). Consensus was defined as more thanCONSENSUS GROUP
MEMBERS
CONCEPT CONSENSUS 
QUESTIONS
FINAL 
CONSENSUS 
QUESTIONS 
INITIATIVE LED BY EOR
SEND TO SOCIETIES 
AS A SURVEY
CONSENSUS 
STATEMENT
DUBLIN 
CONSENSUS 
MEETING
RESULTS OF 
SURVEY
DRAFT CONSENSUS TO
CONSENSUS GROUP ME
Figure 1. Multistep consensus process. EORTC LCG, European O
Group; MDT, multidisciplinary team.75% agreement on a question in the context of the
survey and during the meeting.
Survey
To obtain insight into the dilemmas around the
definition and staging of sOM NSCLC, a questionnaire on
the definition and staging of sOM NSCLC was developed
by the EORTC LCG board members and sent around to
the consensus group. Upon feedback from the consensus
group, the online (Google form) survey was finalized
(Supplementary Table 1). The online survey was
distributed among all consensus group members and all
EORTC LCG and EORTC Radiation Oncology Group
members. National societies were asked to distribute the
survey among their members.
The responses to this survey were used to build the
questions that needed to be discussed during the
consensus meeting. The results were also presented
during the meeting and used in the discussion. The final
results of the survey were presented at the 2018 World
Conference on Lung Cancer (Toronto, Canada).18
Systematic Review
In parallel with the development and distribution of
the survey, a systematic review of the definition and
staging of sOM NSCLC used in publications between
1996 and 2017 was performed. The main selectionCASES
 
TC LCG
SYSTEMATIC 
REVIEW
DISCUSS AT EACH 
LOCAL MDT
SUMMARY OF 
CASE
RESULTS OF
SYSTEMATIC 
REVIEW
ALL
MBERS
rganization of Research and Treatment of Cancer Lung Cancer
Table 2. Consensus Questions Discussed at the Dublin
Meeting
Consensus
Question No. Consensus Question Content
Aim of treatment of sOM NSCLC
1.1 Is it the aim of treatment of patients with OM
NSCLC to achieve cure (to obtain long-term
survival)?
Definition of sOM NSCLC
2.1 Is it the aim of treatment of patients with OM
NSCLC to achieve cure (to obtain long-term
survival)?
2.2 For the definition of sOM NSCLC do you take
into account whether you can treat all
metastatic sites with radical intent?
2.3 For the definition of sOM NSCLC do you take
into account the genomic background of the
tumor?
2.4 How many metastasis are there at a maximum,
regardless of number of organs?
2.5 Is number of organs involved important?
2.6 What is the maximum number of organs with
metastasis (excluding primary) allowed in
sOM NSCLC?
2.7 Would it be helpful to divide OM NSCLC into
stages (i.e., OL1, OL2, OL3, and OL4)?
2.8 Are the specific organs involved with
metastases important?
2.9 When considering specific organ involved
important, which organs would you NOT
involve in your definition of OM NSCLC?
2.10 Is pulmonary metastases considered as 1 site of
metastasis?
2.11 Is mediastinal LN involvement allowed in the
definition of OM NSCLC?
2.12 Is total tumor volume important?
Staging of sOM NSCLC
3.1 Is PET-CT mandatory?
3.2 Is imaging of the brain mandatory?
3.3 Is staging of the mediastinum required?
3.4 Is pathological proof of metastatic disease
(i.e., 1 or all metastatic sites) required?
3.5 When there is a solitary metastasis, is
histological proof needed?
OL, oligo; OM, oligometastatic; sOM, synchronous oligometastatic; LN,
lymph node; PET-CT, positron emission tomography–computed tomography.
2114 Dingemans et al Journal of Thoracic Oncology Vol. 14 No. 12criteria were that sOM NSCLC be the subject and a
definition of sOM be provided; for retrospective studies,
at least 14 patients with sOM NSCLC had to be enrolled.
Reviews were excluded.19
Cases
The cases of 10 real-life clinical patients with sOM
NSCLC (all in good clinical condition, with no comor-
bidities, 18FDG PET and brain magnetic resonance im-
aging [MRI] staging, and <5 metastases) were sent to 33
members of the consensus group. They were asked to
determine, preferably by discussing the cases in their
multidisciplinary team (MDT), whether a case was
considered to be oligometastatic, and if so, what the
proposed treatment should be. These cases were used in
a previous survey, which was presented earlier.20 The
current responses were compared with the 2013 results.
The final results of the survey were presented at 2018
World Conference on Lung Cancer in Toronto, Canada.21
Consensus Meeting
The consensus meeting took place in Dublin, Ireland,
on January 23, 2018. Young investigator members of the
EORTC LCG who were involved in the survey, cases, and
review presented the results of the preparatory work
and recorded the discussion. After a plenary presenta-
tion of the survey, case opinion results, literature review,
and methodology to be used for the consensus process,
the participants were split into two parallel discussion
groups. In each discussion group, led by a senior chair,
all questions had to be answered; young investigators
recorded the discussion. In the last session of the
meeting, the responses of both discussion groups were
presented at the whole group and a consensus to each
scenario was formulated and voted on. After the
meeting, a draft consensus statement was circulated
among the consensus group members, and the
consensus was agreed on and finalized.
Results
Consensus Meeting Preparation
Survey. Between November 25, 2017, and January 18,
2018, a total of 423 physicians from 34 countries and 15
cancer societies (see the Supplementary Data)
completed the survey. These results were presented at
the consensus meeting (the survey was closed on
February 29, 2018, with a total of 444 responders; how
many physicians were invited is not known, as we did
not collect those data). Most (>10%) of the respondents
were from Belgium, Italy, the United Kingdom, and The
Netherlands. The questions extracted from the survey
that were discussed during the consensus meeting are
presented in Table 2.18Systematic Review. The first search identified 1125
potentially eligible abstracts; 73 of them fulfilled the full
set of article selection criteria, and 21 of the articles
were eligible for the systematic analysis. In total, 1215
patients with sOM NSCLC (18–198 patients per article)
were included in these 21 articles. The number of
metastasis allowed in the definition of sOM NSCLC var-
ied between one and eight; more than five metastasis
were allowed in only two out of 21 articles.19
Real-Life Cases. Of the 33 experts (from 24 centers), 26
replied; 62% discussed the cases in their MDT. One case
Table 3. Summary of Consensus Definition OF sOM NSCLC
Consensus
Question Statement
December 2019 Definition of sOM NSCLC—Consensus Report 2115had 100% consensus on the diagnosis of oligometastatic
disease, and three cases had greater than 90%
consensus. For the other cases, agreement ranged from
38% to 69%.21Aim of treatment sOM NSCLC
1.1, 2.1, 2.2 Definition of sOM NSCLC is relevant when a
radical treatment is technically feasible with
acceptable toxicity, with all sites being
amenable to local treatment modality that
may modify the course of the disease and be
considered as an opportunity for long-term
disease control.
Defintion oF sOM NSCLC
2.3 As the definition is not determined by the type
of radical treatment (only by its feasibility),
histologic type and genomic background are
not taken into account in this definition.
2.4, 2.5, 2.6 The maximum number of metastases/organs
involved depends on the possibility of offering
a radical intent treatment strategy. On the
basis of the systematic review, a maximum of 5
metastases and 3 organs is proposed. The
presence of diffuse serosal metastases or bone
marrow involvement excludes cases from this
definition.
2.7, 2.12 Use of risk classification groups or total tumor
volume is of interest, but there is a lack of data
to formulate a statement.
2.8, 2.9 All organs, except diffuse serosal metastases
(meningeal, pericardial, pleural, mesenteric),
and bone marrow involvement are allowed, as
these cannot be treated with radical intent.
2.10 Pulmonary metastases are counted as a
metastatic site.
2.11 Mediastinal lymph nodes should not count as a
metastatic site; mediastinal lymph nodes must
be considered as regional disease. However,
mediastinal lymph node involvement is of
importance in determining whether radical
local treatment of the primary may be
applied.
Staging of sOM NSCLC
3.1, 3.2 18F-FDG PET-CTand brain imaging are mandatory.
For brain imaging, MRI is preferred.
3.3 Mediastinal staging with 18F-FDG PET-CT is
needed, with pathological confirmation
required if this influences treatment strategy.
3.4, 3.5 Pathological confirmation of 1 metastasis is
required unless the MDT decides that the risk
outweighs the benefit.
3.5 In addition to sections 3.2 and 3.3, for a solitary
18Consensus Findings
Of the 35 invited thoracic oncology experts, 26 were
present at the consensus meeting held in Dublin.
Furthermore, four young investigator EORTC LCG
members and the EORTC LCG clinical research physician
were present. Findings from the meeting are presented
in the following paragraphs (see Table 3).
Aim of Treatment of Oligometastatic NSCLC. Defini-
tion of sOM NSCLC is relevant when a radical treatment is
technically feasible with acceptable toxicity, with all sites
being amenable to a local treatment modality that may
modify the course of the disease and may be considered
as an opportunity for long-term disease control (see
Table 3, consensus questions 1.1, 2.1, and 2.2).
The need for “modification of the disease course”
was thought to be important, as it was noted that pa-
tients with sOM NSCLC might have a better prognosis
than patients with more widespread disease, even
without the addition of radical intent treatment. Hence,
the addition of radical treatment should improve the
outcome of patients with sOM disease irrespective of
the pretreatment prognosis. The term long-term disease
control was preferred over the term cure, as it was
believed that patients could benefit from radical treat-
ment resulting in prolonged disease control without
gaining a cure. However, the participants debated
whether toxicity should also be considered and dis-
cussed both in the MDT and with the patient. The term
technical feasibility was added, as it was agreed that
even with a limited number of metastatic sites, radical
treatment may not always be feasible on account of the
location of the metastasis or comorbidities of the pa-
tient. As the definition is not determined by the type of
radical treatment (only by its feasibility), histologic
subtype and genomic background are not taken into
account in this definition.metastasis on F-FDG PET imaging, in specific
cases additional work-up is advised. When the
liver is the only site of oligometastatic disease
a dedicated MRI scan of the liver is advised,
and if a solitary pleural metastasis is
suspected on imaging, then thoracoscopy and
dedicated biopsies of other ipsilateral pleural
sites are recommended, as multifocal disease
is often evidenced in this context during
procedure.
sOM, synchronous oligometastatic. 18F-FDG PET-CT, fludeoxyglucose F 18
positron emission tomography–computed tomography; MRI, magnetic reso-
nance imaging; MDT, multidisciplinary team.Definition of Oligometastatic NSCLC. Maximum Num-
ber of Metastases and Organs. The maximum number of
metastases and organs involved depends on the possi-
bility of offering a radical intent treatment strategy. On
the basis of the systematic review, a maximum of five
metastases and three organs was agreed on. The pres-
ence of diffuse serosal metastases or bone marrow
involvement excludes cases from this definition (see
Table 3, consensus questions 2.4–2.6).
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cantly varied and no consensus was reached on the
maximum number of metastasis or organs. Although
there was agreement that the number of metastasis and
organs involved is important, it was believed that there
is a lack of data on the maximum number that should be
included in a definition. The reason for the disagreement
was the recognition of a lack of prospective data
defining the maximum number of metastasis and organs
that can be technically treated with radical intent and
result in improved outcome (i.e., it was not clear
whether radically treating 10 metastases results in
improved outcome when radical treatment is technically
feasible). In the survey conducted, a maximum of three
metastases was the most frequent answer, but a
maximum of five metastases was the most frequent
definition found in the systematic review. To provide a
workable definition, we combined the maximum num-
ber of metastases and organs with the aim of the
treatment of sOM NSCLC and the results from the sur-
vey. We also discussed the fact that although a large
number of metastasis (i.e., >5) can technically be
treated radically, this is not in line with the term oligo,
and therefore we do not consider this oligometastatic
disease. There was a consensus opinion that prospective
data collection and dedicated clinical trials are needed to
refine the current definition.
Nature of Organs Involved. All organs are allowed, except
diffuse serosal metastases (meningeal, pericardial,
pleural, mesenteric) and bone marrow involvement, as
these cannot be treated with radical intent (see Table 3,
consensus questions 2.8 and 2.9).
Brain and adrenal metastases were not considered to
be special sites, even though there are more data on sOM
in these two organs. The group believed that there could
be publication bias regarding data from these two sites
and that more prospective data on influence of specific
site on outcome are necessary.
Pulmonary Metastases. Pulmonary metastases are coun-
ted as a metastatic site (see Table 3, consensus question
2.10).
For pulmonary metastases, the eighth TNM classifi-
cation should be followed. An M1a lesion counts as one
metastatic site with regard to the definition of oligome-
tastatic disease, Metastasis in the same lobe (T3) or in
the same lung as the primary tumor (T4) should not be
counted as a metastatic site, but it can influence the
possibility of administering treatment with radical intent
depending on the treatment modality or modalities
planned.Mediastinal involvement. Mediastinal lymph nodes should
not count as a metastatic site; mediastinal lymph nodes
must be considered as regional disease. However, medi-
astinal lymph node involvement is of importance in
determiningwhether radical local treatment of the primary
may be applied (see Table 3, consensus questions 2.11).
Given that in some trials mediastinal lymph nodes
counted among the number of metastatic sites15 and
patients with N0 disease seem to have the best prog-
nosis2, whether mediastinal lymph node involvement
should modify the metastatic sites count, provided it
could be amenable to radical treatment, was discussed.
Again, there was agreement that the criteria of the eight
TNM classification should be followed. It was suggested
that future clinical trials consider stratification according
to N0 or N1 versus N2 or N3 status.
Data to Be Collected in Future Trials. Other definition-
related questions were discussed (use of risk classifica-
tion groups, total tumor volume (see Table 3, consensus
questions 2.7 and 2.12), and there was consensus that
these finding are of interest but there is a lack of data to
formulate a statement. It was recommended that data
should be collected in future trials and registries to
evaluate the usefulness of risk classification groups and
total tumor volume.
Staging. Imaging work-up. 18F-FDG PET–computed to-
mography and brain imaging are mandatory. For brain
imaging, MRI is preferred (see Table 3, consensus
questions 3.1 and 3.2).
There was 100% agreement on these staging in-
vestigations, which was in keeping with the recently
published EORTC recommendations.22
Mediastinal Staging. Mediastinal staging with 18F-FDG
PET–computed tomography is needed, with pathological
confirmation required if this influences treatment strat-
egy (see Table 3, consensus question 3.3).
There was extensive discussion as to whether medi-
astinal staging with endobronchial/esophageal ultra-
sound and/or mediastinoscopy should be performed to
obtain the most reliable staging information (i.e.,
following the same principles as for early-stage dis-
ease).23 However, for practical reasons it was agreed to
request pathological confirmation only if it would influ-
ence the treatment strategy (e.g., whether to perform
lobectomy, whether to include mediastinal lymph nodes
in the radiation field).
Pathological Confirmation. Pathological confirmation of
at least one metastasis is required unless the MDT
December 2019 Definition of sOM NSCLC—Consensus Report 2117decides that the risk outweighs the benefit. (see Table 3,
consensus questions 3.4 and 3.5).
This is especially important in the case of a solitary
metastasis and if it may change the therapeutic strategy,
including scenarios with mediastinal nodal involvement.
Solitary Metastasis. In addition to sections 3.2 and 3.3,
for a solitary metastasis on 18F-FDG PET, in specific
cases additional work-up is advised. When the liver is
the only site of oligometastatic disease, a dedicated MRI
scan of the liver is advised, and if a solitary pleural
metastasis is suspected on imaging, then thoracoscopy
and dedicated biopsies of other ipsilateral pleural sites
are recommended, as multifocal disease is often evi-
denced in this context during procedure (see Table 3,
consensus question 3.5). Of note, pleural malignant
effusion is not considered amenable to radical treatment
to date.
Discussion
This is the first multidisciplinary formulated
consensus statement on the definition and staging of
sOM NSCLC. The work of the group includes results of a
European survey, a systematic review, and real-life case
discussions followed by a consensus meeting. This
statement is needed to standardize inclusion criteria in
future clinical trials, as well as to aid in prospective data
collection, make results of the clinical trials comparable,
and guide treatment discussion in MDT meetings. The
aim of the working group was to be as inclusive as
possible and avoid controversial extremes in order to
settle on a clinically relevant consensus. Whereas there
is no high-level evidence for a definition or staging of
sOM NSCLC, we followed a rigorous multistep process to
formulate this consensus. On the basis of the process
that we followed and the extensive discussions with all
the experts during the consensus meeting, we believe
that this consensus statement will represent an oppor-
tunity, with endorsement of several societies involved in
lung cancer treatment, to standardize the definitions,
diagnosis, and assessment of oligometastatic disease. We
acknowledge that although the definition of sOM NSCLC
might change over time when more prospective data
become available, this work provides a framework for
such future research.
One of the important areas of disagreement in the
survey and during the consensus meeting was the
maximum number of metastases and organs allowed in
the definition. Thanks to new treatment techniques, a
large number of metastases can often be treated with
radical intent. However, whether LRT improves outcome
in these patients is not known. During the consensus
meeting discussions, it was stated several times that thenumber of metastatic sites is not important if LRT is
possible. This was also the position of only 16% of the
survey responders, supporting the controversy.18 How-
ever, the systematic review found that even if trials
allowed up to five metastases, in reality the patients
enrolled in these trials often had only one or two me-
tastases. Although in the real-life cases only patients
with up to four metastases were included, we think that
this did not affect the outcome, as the restriction to a
single or two metastases was also common in the pro-
vided answers to the real-life cases.21 In the end,
considering that oligo means “few” and with support
from published data, we agreed that more than five
metastases should not currently be allowed in the defi-
nition of oligometastatic disease. We believe that feasi-
bility, safety, and amenability to radical treatment
globally might still impose this constraint. To obtain
more information, prospective registries should collect
data on all patients treated with LRT to also evaluate
outcome with LRT in patients with nonoligometastatic
disease (e.g., EORTC/EORTC-RP-1822 E2-RADIatE [Oli-
goCare: A Pragmatic Observational Cohort Study to
Evaluate Radical Radiotherapy for Oligo-metastatic
Cancer Patients]) to define the optimal number of
metastasis and metastatic sites suitable for LRT.
Although it is known that involvement of mediastinal
lymph nodes has prognostic value in stage IV NSCLC
with single-organ metastasis24 and sOM NSCLC,2 this
was not taken into account in the eighth TNM classifi-
cation.25 We agreed that metastatic mediastinal lymph
nodes should be allowed in the oligometastatic definition
but not counted as a metastatic site and that ideally N
categories should be used as an additional stratification
factor, supporting MDT decisions, as we recognized that
its involvement has prognostic significance.
The 5-year OS data from the two randomized phase II
trials15,16 are awaited, but the long-term OS data from
the first single-arm phase II trial12 are already available.
In this trial, patients with sOM NSCLC at diagnosis (not
after induction treatment) were treated with radical
intent. The 5- and 6-year OS rates were disappointingly
low, being only 7.7% and 5.1%, respectively.26 With
regard to the ongoing clinical trials, the randomized
phase III SARON trial (NCT02417662) is designed to
address the question as to whether LRT will improve OS
in patients with sOM SCLC.27 In this trial, patients with
EGFR/ALK receptor tyrosine kinase (ALK)-negative
NSCLC with sOM disease will be registered before
treatment, and when no progression occurs after two
cycles of chemotherapy, patients will be randomized
between two additional cycles of chemotherapy with or
without local ablative radiotherapy. In this trial, staging
with 18F-FDG PET and brain imaging is mandatory and a
2118 Dingemans et al Journal of Thoracic Oncology Vol. 14 No. 12maximum of three metastatic lesions is allowed. The
primary outcome measure is OS. Patients are stratified
according to presence versus absence of mediastinal
lymph node metastasis (N0 or N1 versus N2 or N3),
number of metastasis (one versus two or three), and
presence versus absence of brain metastasis.
On the basis of our results, besides the number of
metastases, number and type of organs with metasta-
ses, and involvement of mediastinal lymph nodes, other
areas for future research are (1) the prognostic sig-
nificance of total tumor volume and histological sub-
type and (2) the significance of dividing sOM NSCLC
into risk groups (e.g., group 1, one metastasis in one
organ; group 2, two or three metastases in one organ;
and group 3, two or three metastasis in two organs).
Ideally, ongoing registries and trials (e.g., EORTC Oli-
goCare, SARON) should collect prospective data on
these topics.
In addition to working toward an agreed-on defini-
tion of sOM NSCLC, clarifying the staging requirements is
also essential. The EORTC Imaging Group published
recently imaging recommendation for oligometastatic
NSCLC to correctly identify these patients.22 For lung
cancer, an 18F-FDG PET scan and a dedicated brain MRI
scan are recommended, the same as proposed for stage
III NSCLC.28 During our consensus process, we also
established the importance of adequate staging, as 18F-
FDG PET and brain imaging can upstage tumors and
result in preventing unnecessary toxicity for patients
with nonoligometastatic disease.
The major limitation of our work is the lack of evi-
dence (as shown by the results of the systematic review
and the variation in answers in the survey and real-life
cases). In addition, this consensus definition represents
the view of European lung cancer experts, which might
not reflect the opinion of experts outside of Europe.
In conclusion, through a rigorous multistep process
taking into account results of a systematic review, a
European survey, and real case discussions, a multidis-
ciplinary consensus statement on the definition and
staging of sOM SCLC was formulated. This statement will
help to harmonizing inclusion criteria in future clinical
trials.
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